Pharvaris N.V.
PHVS
$21.71
$0.070.32%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
11/3/2025
-
ETF Channel
10/30/2025
-
Tickeron - Stocks
10/29/2025
-
Tickeron - Stocks
10/28/2025
-
Tickeron - Stocks
10/26/2025
-
Ticker Report
10/25/2025
-
MarketBeat
10/25/2025
-
Tickeron - Stocks
10/24/2025
-
Tickeron - Stocks
10/23/2025
-
GuruFocus
10/23/2025
-
Globe Newswire
10/23/2025
-
Tickeron - Stocks
10/22/2025
-
Tickeron - Stocks
10/22/2025
-
Tickeron - Stocks
10/22/2025
-
MarketBeat
10/21/2025
-
Tickeron - Stocks
Pharvaris (PHVS, $23.63) entered Uptrend as Momentum indicator ascends above 0 level on Oct 20, 2025
10/21/2025
-
Tickeron - Stocks
10/21/2025
-
Tickeron - Stocks
10/21/2025
-
Tickeron - Stocks
10/20/2025
-
MarketBeat
10/20/2025
-
Simply Wall St
10/19/2025
-
Simply Wall St
10/17/2025
-
MarketBeat
10/16/2025
-
MarketBeat
10/16/2025
-
Tickeron - Technical Analysis
10/15/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
31 712036410
Address
Grafenauweg 8
Zug, 6300
Zug, 6300
Country
Year Founded
Business Description
Sector
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other...
more